Gut microbial metabolite urolithin B protects from insulin resistance and intestinal inflammation in association reshaping gut microbiota of obseity mice

Peng Chen,Wang rong,Jiexin Lei,feng lihua,Benhong Zhou
DOI: https://doi.org/10.1039/d4fo02545h
IF: 6.3173
2024-06-12
Food & Function
Abstract:We aimed to investigate the metabolic impact of urolithin B (Uro B) on high fat/high sucrose (HFHS)-fed mice and to determine whether its consequent antidiabetic effects are related to modulations in the gut microbiota. Design C57BL/6J mice were fed either a chow or a HFHS diet. HFHS-fed mice were gavaged daily either with vehicle (water) or Uro B (200 mg/kg) for 8 weeks. The composition of the gut microbiota was assessed by analysing 16S rRNA sequencing. The results showed that Uro B treatment could reduce HFHS-induced weight gain and visceral obesity, decrease liver weight and triglyceride accumulation in association with blunted hepatic oxidative stress and inflammation. Furthermore, Uro B administration improved insulin sensitivity, as revealed by improved insulin tolerance, lower homeostasis model assessment of insulin resistance and decreased glucose-induced hyperinsulinaemia during an oral glucose tolerance test. Uro B treatment was found to lower intestinal triglyceride content and to alleviate intestinal inflammation and oxidative stress. Interestingly, Uro B treatment markedly increased the proportion of the mucin-degrading bacterium Akkermansia in our metagenomic samples. Conclusions Uro B exerts beneficial metabolic effects through improving HFHS diet-induced features of the metabolic syndrome, which is associated with a proportional increase in Akkermansia spp. population.
biochemistry & molecular biology,food science & technology
What problem does this paper attempt to address?